Argenx Shares Plunge After Autoimmune-Disease Trial Halt
The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.
Connecting Global Economies
Flash News
What Growing Up on a Farm Taught Elanco’s CEO
Breaking | Canada’s Anne Carson wins 2026 Nobel Prize in Literature
PepsiCo (PEP) Q3 2026 earnings
Sebastian Stan Details Bald Hair Transformation in Fjord
Justice Democrats announce new executive director
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
Kagan, Soai win Nobel Chemistry Prize for solving chemical asymmetry puzzle
China’s real estate market may be set for a turnaround, S&P says
Ben Affleck Did Not Wear Prosthetic in Gone Girl Shower Scene
Chinese consortium to build Latin America’s longest cable-stayed bridge in Brazil
Thursday, October 08, 2026
